Lifeward completed a financing that delivers $5.58 million in senior secured convertible notes with accompanying warrants, and established a second $5.58 million tranche subject to performance or share price milestones. The notes carry an 8% interest rate (15% upon default), mature in three years, and convert at $5.40 per share, while the warrants cover 100% of potential conversion shares and are exercisable immediately for five years. In parallel, Lifeward amended existing secured notes and warrants to provide pari passu treatment with the new issuance and to refine redemption and ownership limit terms, aligning its capital structure for future growth.
Agreement 1: Lifeward Raises $5.58M in Secured Convertibles With Warrants; Second $5.58M Tranche Contingent
- Agreement type: Senior secured convertible notes and accompanying warrants under a securities purchase agreement
- Counterparty: Oramed Pharmaceuticals and certain investors
- Signed / Effective: Jun 30 2026 / Jul 06 2026
- Duration / Termination: 3 years
- Reason: Raise capital for operations and growth
Agreement 2: Lifeward Amends Secured Notes and Warrants to Align Pari Passu and Ownership Limits
- Agreement type: Amended and Restated Senior Secured Convertible Note, Warrant and Pre-Funded Warrant
- Counterparty: Oramed Pharmaceuticals and certain investors
- Signed / Effective: Jun 30 2026 / same
- Reason: Standardize terms and cap beneficial ownership
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.